Characteristics and outcomes of women initiating ART during pregnancy versus breastfeeding in Option B+ in Malawi by unknown
RESEARCH ARTICLE Open Access
Characteristics and outcomes of women
initiating ART during pregnancy versus
breastfeeding in Option B+ in Malawi
M. Landes1,2*, S. Sodhi1,2, A. Matengeni1, C. Meaney2, M. van Lettow1,3, A. K. Chan1,4 and J. J. van Oosterhout1,5
Abstract
Background: Malawi adopted the PMTCT strategy ‘Option B+’ in 2011, providing life-long ART for all HIV-infected
pregnant and breastfeeding women. We explored differences in characteristics and outcomes of women initiating
ART during pregnancy versus breastfeeding.
Methods: We conducted a retrospective cohort analysis of women in Zomba District, southern Malawi, from
January 2012- September 2013. Data were extracted from the Zomba District Observational Cohort Study, a
surveillance project collecting data from standardized Ministry of Health ART monitoring tools.
Results: 1986 (67.2 %) women initiated ART during pregnancy and 969 (32.8 %) during breastfeeding. Women
initiating ART in breastfeeding were more likely to be > 30 years (aOR = 1.33, 95 % CI1.11–1.59, p = 0.003) and
have WHO Stage 3/4 (aOR = 2.74, 95 % CI1.94–3.87, p < 0.001).
Eighteen (0.6 %) deaths occurred and 942 (31.9 %) women defaulted ART. ‘Early’ death (< 30 days) occurred in
3 (0.1 %) women and 449 (16.4 %) women defaulted early. Death/default < 30 days was more likely among women
initiating ART during pregnancy (aOR 1.62, 95 % CI1.28–2.05, p < 0.001) or < 30 years old (aOR 1.27, 95 % CI 1.02–1.57,
p = 0.03) and was less likely among those with WHO Stage 3/4 (aOR 0.30, 95 % CI 0.15–0.60, p < 0.001).
Using Kaplan-Meier estimators to investigate time to death/default, we showed a sharp drop in death/default-free
survival probability at time zero, yet survival probability decreased in a nearly linear manner after this initial period of
high default. Women under 30 years had increased rates of death/default over time (log rank test: p < 0.001),
however no significant differences were observed in death/default over time associated with timing of ART
initiation, documented clinical stage at initiation, health clinic size or adherence rates.
Conclusions: Many women in Malawi started ART during breastfeeding within Option B+ and were older and
had more advanced WHO Clinical Staging. This represents a missed PMTCT opportunity to initiate treatment
early in pregnancy. Early defaulting is identified as a challenge within Option B+, and was more likely among
younger women and those initiating ART in pregnancy. Targeted research to understand factors associated
with uptake of ART during pregnancy and retention in care could improve the efficacy of Option B+ in Malawi.
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Background
In 2011, the Malawi Ministry of Health (MoH) adopted
a national program for the prevention of mother to child
transmission (PMTCT) of HIV called ‘Option B+’, which
provides life-long antiretroviral therapy (ART) for all
HIV-infected pregnant and breastfeeding women regard-
less of clinical or immunological stage.
Since the introduction of Option B+, aggregated na-
tional data have shown a 6-fold increase in the number
of pregnant women initiating ART in Malawi with an
estimated 28,000 women accessing ART annually across
the country [1].
Additionally, national program monitoring suggests a
fairly high level of retention among women initiating
ART in Option B+, with estimated retention rates of
72 % at 12 months and 68 % at 24 months [1]. Recent
studies however highlight challenges around early default-
ing in women initiating ART through Option B+ with
women either failing to start ART (i.e. immediate default-
ing) or defaulting at less than 6 months [2, 3].
While national guidelines encourage early identifica-
tion of HIV-infected women in pregnancy through test-
ing and early initiation of ART at antenatal clinics
(ANC), program data consistently show that at least
one-fifth of women initiate ART later in the breastfeed-
ing period [1]. This delayed initiation of ART represents
a missed opportunity for preventing HIV transmission
in utero, during delivery and in the early postpartum
stages. Reasons for delayed ART initiation among these
women may include late or missed identification at
ANC and delivery (including non-attendance at ANC or
refusal of HIV testing), incident HIV infection in preg-
nancy or women re-initiating ART after defaulting dur-
ing pregnancy [1].
Limited description exists of the differences between
women initiating ART during pregnancy or breastfeed-
ing, both in terms of characteristics associated with the
timing of ART initiation and their outcomes within the
Option B+ program. We conducted a retrospective co-
hort analysis within the Zomba Observational Cohort
Study, a population-based observational cohort of ART
patients in southeastern Malawi, in order to investigate
differences between the characteristics of women either
initiating ART in pregnancy or during the breastfeeding
period. Additionally we investigated the relationship be-
tween timing of ART initiation and time to death or
default.
Methods
Study design and setting
A retrospective cohort analysis was conducted includ-
ing all women in the Zomba District of southern
Malawi who initiated ART from January 1, 2012
through September 30, 2013. Malawi is a developing
country in sub-Saharan Africa with an HIV prevalence
of 10.6 % among 15–49 year olds. By the end of 2014,
more than 500,000 persons were alive on ART, indicat-
ing that close to 50 % of all HIV-infected Malawians
were on ART [1]. PMTCT care was provided in all
health centres according to the Option B+ strategy as
per national MoH guidelines starting in 2011 [4]. Preg-
nant or breastfeeding mothers received HIV-testing and
counselling in antenatal care clinics or Under-5 Clinics
and HIV-infected women were offered life-long ART
regardless of clinical or immunological stage. All
women were initiated and followed either in the ANC
clinic or in a linked ART clinic.
Data collection
Demographic, clinical and outcome data were extracted
from the Zomba District Observational Cohort Study
database. This cohort study routinely collects individual
level HIV care information from 31 health centres (8
urban, 23 rural) in Zomba District via standard Malawi
MoH ART monitoring tools. Methods for data collection
have been described previously [5]. Ethics approval for
the study was received from the Malawi National Health
Services Research Committee, Malawi and the University
Health Network, Toronto, Canada.
Patient characteristics were categorized as: age (< 30 years;
> = 30 years), size of health facility at which they re-
ceived care (<100 patients on ART; 100–500 patients
on ART; 500+ patients on ART), WHO clinical stage
on ART initiation (Stage 1; Stage 2; Stage 3–4; un-
known stage) and ART adherence rates defined as per-
centage of self-reported pills remaining out of those
prescribed from the last visit (< 95 % adherence; > =
95 % adherence). Patient outcomes were classified as ei-
ther: alive and on ART, dead or defaulted (failed to visit
their clinic within 2 months after the next appointment
date or stopped ART).
Statistical methods
Descriptive statistics were used to summarize character-
istics of our sample. Contingency tables and Pearson’s
chi-squared tests were used to describe unadjusted rela-
tionships between timing of ART initiation and covariates.
Multivariate logistic regression was used to estimate
unadjusted/adjusted odds of initiating ART during
breastfeeding.
Further, bivariate and adjusted multivariate analysis
were used to investigate timing of ART initiation and
its impact on time to death/default (as a composite out-
come variable). We considered two operational defini-
tions of death/default: first, we investigated whether a
women had died/defaulted within 30 days of ART initi-
ation, censoring those women with no observed out-
come (lacking confirmed data) within 30 days. Similar
Landes et al. BMC Public Health  (2016) 16:713 Page 2 of 7
methods for categorical data analysis as those described
above were used to investigate the association between
covariates and the odds of death/default within 30 days
of ART initiation. Sensitivity analyses of death/default
within 90 days and 365 days of ART initiation, were
performed and inferences from models fit to these out-
come data were similar to those from the 30 day re-
sponse models. As such, results of the sensitivity
analyses are not shown. Additionally, we explored the
association between death/default-free survival using
Kaplan-Meier survival analysis estimators and log-rank
tests. These methods are capable of accounting for cen-
soring of the outcome variable (death/default) and com-
plement the categorical data analysis approach outlined
above. All statistical analyses were conducted in SAS ver-
sion 9.4 (SAS Corporation, Cary, North Carolina).
Results
Description of cohort
Overall, 2955 women initiated ART during the study
period. Data were recorded for initial ARV regimen in
2730 (92.4 %) women, of which 2658 (97.4 %) started
the Option B+ first line ART regimen (a generic, one-
tablet formulation of tenofovir, lamivudine and efavir-
enz). The median age in our sample was 29 years (IQR:
24–33). WHO Clinical Stage at enrolment was recorded
for 2153 (72.9 %) women: 1777 (82.5 %) of whom were
WHO Clinical Stage 1 and 1983 (92.1 %) were either
Stage 1 or Stage 2. Adherence data were available for
2138 (72.4 %), women of whom 2090 (97.8 %) had an
adherence of > =95 %.
Initiation of ART
Of the 2955 women in the sample, 1986 (67.2 %) initi-
ated ART during pregnancy and 969 (32.8 %) during
breastfeeding (Table 1). Women initiating ART in
breastfeeding were more likely to be older (> 30 years;
aOR = 1.33, 95 % CI 1.11, 1.59, p = 0.003) and have ad-
vanced WHO Clinical Stage (Stage 2 or Stage 3 and 4)
at the time of enrolment (aOR = 1.59, 95 % CI 1.15–2.18,
p = 0.005 and aOR = 2.74, 95 % CI 1.94–3.87, p < 0.001)
(Table 2).
Death or treatment default
Among the 2955 women in the cohort, we observed 18
(0.6 %) confirmed deaths of which 13 (72.2 %) occurred
among women in WHO Clinical Stage 1 or 2 at the time
of ART initiation. 1995 (67.5 %) women were observed
as retained on ART and 942 (31.9 %) women were re-
corded as having defaulted ART, of whom 396 (42.0 %)
did not return after the ART initiation visit.
In the following section we describe early death/de-
fault occurring within 30 days of ART initiation. We
observed early death in 3 (0.1 %) women and early
defaulting in 449 (16.4 %) women. Table 3 shows bivari-
ate and multivariate associations between maternal
characteristics and the probability of death or default
within 30 days. Death or default by 30 days was more
likely among women initiating ART during pregnancy
(aOR 1.62, 95 % CI 1.28–2.05, p < 0.001) and who were
less than 30 years old (aOR 1.27, 95 % CI 1.02–1.57, p
= 0.03). Women with WHO Stage 2 and 3–4 had lower
adjusted odds of 30 day death or default compared to
women with WHO Stage 1 (aOR 0.62, 95 % CI 0.39–
0.98, p = 0.04; aOR 0.30, 95 % CI 0.15–0.60, p < 0.001
respectively).
In Fig. 1, we further investigate death/default free sur-
vival experiences of women in this cohort using Kaplan-
Meier estimators. A large number of women had zero
follow-up time which results in a sharp drop in the
death/default free survival probability at time zero. The
estimated survival probability decreases in a nearly linear
manner after the initial period of high default. Overall,
the median death/default free survival time in this co-
hort is estimated to be 596 days.
Figure 2a-b illustrate the association between maternal
characteristics and death/default free survival. In Fig. 2a,
we observed that the protective effect from death/default
of initiating ART during breastfeeding was attenuated
after 1-year following treatment initiation and we see
that at 1-½ years post ART initiation the probability of
death/default was roughly the same in women initiating










< 30 years 1293 (65.4 %) 565 (58.5 %) < 0.001
> 30 years 685 (34.6 %) 401 (41.5 %)
Health Facility Sizea
Small (< 100) 45 (2.3 %) 29 (3.0 %) 0.06
Medium (100–500) 1674 (84.3 %) 836 (86.3 %)
Large (> 500) 267 (13.4 %) 104 (10.7 %)
WHO Clinical Stage
at Initiation
Stage 1 1241 (62.5 %) 536 (55.3 %) < 0.001
Stage 2 119 (6.0 %) 87 (9.0 %)
Stage 3–4 75 (3.8 %) 95 (9.8 %)
Not documented 551 (27.7 %) 251 (25.9 %)
Adherence Rates
> 95 % 1330 (97.4 %) 766 (98.3 %) 0.18
< 95 % 35 (2.6 %) 13 (1.7 %)
aBased on number of patients on ART at health facility
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during pregnancy/breastfeeding. Ultimately, we fail to
reject the null hypothesis that death/default-free survival
between women initiating ART pregnancy and breast-
feeding is different over the duration of follow up time
in the study (log-rank test: p = 0.12). However, Fig. 2b
suggests that women under 30 years of age have reduced
death/default free survival compared to older women
(log rank test: p < 0.001). This finding is consistent
across the time course of the study. We observed no sig-
nificant differences in the death/default-free survival of
women in documented different clinical stages, from dif-
ferent sized health facilities, or of women with different
treatment adherence rates (Kaplan-Meier analysis results
not shown).
Table 2 Association between maternal characteristics and the probability of initiating ART during breastfeeding
Unadjusted Odds Ratios Adjusted Odds Ratios
OR 95 % CI P-value aOR 95 % CI P-value
Age
< 30 years — — — — — —
> 30 years 1.34 1.14, 1.57 < 0.001 1.33 1.11, 1.59 0.003
Health Facility Sizea
Small (< 100) — — — — — —
Medium (100–500) 0.78 0.48, 1.25 0.29 0.78 0.45, 1.35 0.37
Large (> 500) 0.60 0.36, 1.02 0.06 0.65 0.36, 1.17 0.15
WHO Clinical Stage at Initiation
Stage 1 — — — — — —
Stage 2 1.69 1.26, 2.27 < 0.001 1.59 1.15, 2.18 0.005
Stage 3–4 2.93 2.13, 4.03 < 0.001 2.74 1.94, 3.87 < 0.001
Not documented 1.06 0.88, 1.26 0.56 1.18 0.95, 1.47 0.14
Adherence Rates
= > 95 % — — — — — —
< 95 % 1.55 0.82, 2.95 0.18 1.50 0.78, 2.88 0.22
a Based on number of patients on ART at health facility
Table 3 Factors associated with death/default at 30 days (N = 2670)
Unadjusted Odds Ratios Adjusted Odds Ratios
OR 95 % CI P-value aOR 95 % CI P-value
Timing of ART Initiation
In Pregnancy 1.72 1.37, 2.17 < 0.001 1.62 1.28, 2.05 < 0.001
In Breastfeeding —
Age
< 30 years 1.33 1.07, 1.65 0.01 1.27 1.02, 1.57 0.03
> 30 years —
Health Facility Size
Small (< 100) — — —
Medium (100–500) 1.00 0.52, 1.92 0.99
Large (> 500) 1.19 0.59, 2.41 0.62
WHO Clinical Stage at Initiation
Stage 1 — — — — — —















Adjusted for timing, age and clinical stage
If a woman was not observed for at least 30 days, they are removed from the analysis
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Discussion
In this study, we report on a large number of HIV-
infected pregnant or breastfeeding women initiating
ART under the Option B+ strategy at a time when it
was well established in the rural southeast health-zone
of Malawi. We found that a high percentage of women
(32.8 %) initiated ART during breastfeeding and that this
was associated with older age and more advanced HIV
disease (WHO Stage > 1). Overall recorded mortality
was very low (0.6 %), but overall defaulting was consid-
erable (31.9 %). We also found that risk of early death/
defaulting (< 30 days) was higher in women who started
ART in pregnancy and in younger women (< 30 years)
and lower in those with more advanced HIV disease
(WHO Stage > 1). However, while initial differences are
seen in early defaulting between women starting ART
during pregnancy and breastfeeding, survival analysis
demonstrated that this difference faded at longer follow
up and was ultimately non-significant.
By using routinely collected data from the Zomba Ob-
servational Cohort Study, we are able to describe indi-
vidual characteristics and outcomes for this cohort. Our
data reflect national monitoring reports in that while the
majority of women initiated ART during pregnancy, an
important proportion continue to have delayed initiation
of ART during breastfeeding [1]. We report that women
initiating ART during breastfeeding were more likely to
be older and to have more advanced HIV disease. This
suggests there may be differing motives for entering care
among these two groups. It is possible that women initi-
ate ART during breastfeeding period because of symp-
toms that bring them to seek care at a health facility
whereas routine HIV-testing in pregnancy captures a lar-
ger proportion of asymptomatic women. Regardless, the
delayed initiation of ART within the PMTCT cascade
and increased prevalence of advanced HIV disease (sug-
gesting higher HIV1-RNA levels) among these women
raises concerns for increased mother to child transmis-
sion of HIV. Interventions to encourage earlier presenta-
tion to ANC for HIV testing and ART initiation may
improve outcomes in Option B+.
Overall, we report moderately high rates of retention
and high levels of self-reported adherence among a
largely asymptomatic, and predominantly rural cohort.
These results are comparable to facility level nation-
wide reports from the Malawi HIV programme and to a
study that utilized individual level analyses from mostly
urban, large Malawian health facilities with electronic
monitoring systems and one further study from urban


































Days Since ART Initiation
Fig. 1 Kaplan Meier estimates of death/default free survival probability in the overall cohort
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above we also show that the largest risk for defaulting
exists early after starting ART [1–3].
Additionally, we report that women initiating ART in
pregnancy were more likely to be early defaulters than
women initiating ART during breastfeeding. This agrees
with a recent study from Malawi in which women initi-
ating ART during pregnancy had higher default rates at
6 months than those initiating during breastfeeding [2].
It is possible that timing of HIV diagnosis and ART initi-
ation itself may be a factor associated with risk of early
defaulting among women in Option B+. Recent evidence
describes that both women and health care providers
identify that a new HIV diagnosis during routine ante-
natal screening can be accompanied by varying degrees
of shock and denial and may lead to difficulty accepting
immediate initiation of lifelong treatment, in particular
among the mostly asymptomatic pregnant women at
ANC clinics [7, 8]. Furthermore, it has recently been re-
ported that receiving a new HIV diagnosis and ART ini-
tiation on the same day increases this risk of early
defaulting [2, 9] and that the model of care for PMTCT
at health centres in Malawi, including how timing of
HIV testing and ART initiation is structured, can impact
overall uptake and retention [10].
Given that we report that women who initiate ART
during breastfeeding were more likely to be older and
present with more advanced HIV disease, lower rates of
early defaulting in this group may also reflect differing
individual patient motivations for initiating and continu-
ing on ART. Tweya et al. showed similar lower rates of
loss to follow-up among women initiating during breast-
feeding in Malawi [11]. While illness has been cited as a
reason for defaulting ART in Option B+ in Malawi [11],
a further recent qualitative study in Malawi notes that
both fear of future sickness or a current decline in health
prompted women who had already stopped ART in
Option B+ to re-start later (either during pregnancy or
breastfeeding) [12]. Further research to understand pa-
tient characteristics, experience and motivations that
lead to improved earlier uptake of ART and subsequent
adherence should be incorporated into programmatic
adaptations of Option B+.
Finally, we highlight that younger age remained the
most consistent risk factor for defaulting both early after
initiation and over the course of follow-up in the study.
In the previously mentioned study by Tweya et al.,
younger age (< 24 years) was similarly associated with an


































923 778 688 626 563 497 440 365 295 217 115 38 Initiation=Breastfeed
1824 1380 1175 1029 877 728 631 494 362 247 135 34 2 Initiation=Pregnancy
Breastfeeding
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1022 832 708 636 565 483 434 355 267 194 110 33 2 Age=Over 30
1717 1319 1150 1015 871 739 635 502 388 269 139 39 Age=Under 30
Over 30
Under 30
Days Since Treatment Initiation
a b
Fig. 2 Kaplan Meier estimates of death/default free survival probability stratified by a timing of treatment initiation (breastfeeding versus pregnancy)
and b age (less than 30 years of age versus greater
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cohort in Malawi [11]. Reasons for higher defaulting
among younger women remain to be understood in
women in Option B+ and further research could identify
both reasons for this association along with potential
mechanisms for targeting support for younger women in
care.
Limitations
There are several limitations to this study. Lack of a de-
faulter tracing system may underestimate mortality for
women initiating within Option B+ as well as their re-
tention, as recent Malawian data found that a relevant
proportion of traced defaulters had either died or self-
transferred to other care [10]. Additionally, we relied on
routine data collection using national standardized ART
monitoring forms, which may have limited the quality of
the data. Specifically, as women are enrolled in Option B+
regardless of stage, data on WHO clinical staging may be
less reliably documented and was missing in just over 1/4
of all women. Finally, adherence measures on standard-
ized ART cards are limited to self-report of doses missed
since last appointment.
Conclusions/recommendations
While early identification and initiation of ART among
pregnant women is encouraged in the Option B+ Program
in Malawi, many women continue to start ART during
breastfeeding. These women were older, more often in
WHO Clinical Stage 2, 3 or 4 and had a lower risk of early
death/default compared to those starting during preg-
nancy. Starting ART during breast feeding represents a
missed PMTCT opportunity during the antenatal phase
and delivery. Additionally, early defaulting is identified as
a challenge within Option B+, and was more likely among
younger women and those initiating ART in pregnancy.
Targeted research to understand factors associated with
the uptake of ART during pregnancy and retention in care
could improve the efficacy of Option B+ in Malawi by
informing targeted programmatic interventions.
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